

KURZPROTOKOLL PANTHEON

Öffentlicher Titel	Phase II Studie zum Überleben nach sequenzieller Chemotherapie des metastasierten Bauchspeicheldrüsenkrebs
Wissenschaftl. Titel	A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON)
Kurztitel	PANTHEON
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, zweiarmig, Investigator Initiated Trial (IIT)
Studienphase	Phase II
Erkrankung	Verdauung: Bauchspeicheldrüsenkrebs (Pankreaskarzinom): Zweitlinie oder höher
Einschlusskriterien	<ul style="list-style-type: none">- Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations- Age \geq 18 years at time of study entry Unresectable adenocarcinoma of the pancreas previously treated in the palliative setting with gemcitabine and nabpaclitaxel (Abraxane®)- Adequately documented recurrence and disease status after/under 1st line (Best response, duration of treatment, time to progression, preexisting PNP and other side effects)- Radiologically confirmed disease progression during 1st-line therapy and measurable reference cancer site(s) as defined by RECIST1.1- Randomization and start of 2nd-line treatment possible within 4 weeks after radiologically documented disease progression during 1st-line therapy- ECOG performance status 0-2 8. No prior radiotherapy- Adequate blood count, liver-enzymes, and renal function:<ul style="list-style-type: none">- Absolute neutrophil count (ANC) \geq $1.5 \times 10^9/L$ (> 1500 per mm^3)- Platelet count \geq $100 \times 10^9/L$ ($>100,000$ per mm^3)- AST (SGOT)/ALT (SGPT) < 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be $< 5x$ ULN- Serum creatinine CL \geq 60 mL/min calculations according to local standard- Bilirubin < 3 ULN 10. Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: 60 years old and no menses for \geq 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Ausschlusskriterien	<ul style="list-style-type: none">- Serious cardiovascular disease (eg, unstable coronary artery disease or myocardial infarction within 3 months prior to study start)- Preexisting polyneuropathy (PNP) \geq grade 3 [National Cancer Institute Common Toxicity Criteria grade 3 or 4 sensory or motor neuropathy]- Prior or concurrent malignancy (other than pancreatic cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin- History of DPD deficiency- Morbus Gilbert- History of hypersensitivity to any of the study drugs or any of the constituents of the products- Medication that is known to interfere with any of the agents applied in the trial

KURZPROTOKOLL PANTHEON

- Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year)
- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- Any medical condition that contraindicates dosing with any of the IMPs or constitutes a safety risk for the patient including but not limited to:
 - - chronic inflammatory bowel disease and/or bowel obstruction.
 - - active uncontrolled infection
 - - clinically significant bleeding or bleeding diathesis
 - - clinically significant stomatitis
 - - active ulceration of the gastrointestinal tract
- Previous enrollment or randomization in the present study (does not include screening failure)
- Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG]

Alter

18 Jahre und älter

Prüfzentren

Agaplesion Markus Krankenhaus (Geschlossen)

Wilhelm-Epstein-Straße 4

60431 Frankfurt am Main

Dr. med. Claus Bolling

Tel: 069 95332206

Fax: 069 95332098

claus.bolling@fdk.info

Innere Medizin 1 (Geschlossen)

Gastroenterologie / Hepatologie

Theodor-Stern-Kai 7

60590 Frankfurt am Main

Wina Hensel

Tel: 069 6301-87769

Fax: 069 6301-6580

wina.hensel@kgu.de

Universitätsklinikum Frankfurt (Geschlossen)

Medizinische Klinik I, Gastroenterologie/Hepatologie

Theodor-Stern-Kai 7

60590 Frankfurt am Main

Wina Hensel

Tel: 069 6301-87769

Fax: 069 6301-6580

wina.hensel@kgu.de

Sponsor

AIO-Studien GmbH

**Registrierung in anderen
Studienregistern**

EudraCT 2016-004640-11

ClinicalTrials.gov NCT03331640